Loading...
XTAI4746
Market cap261mUSD
Dec 24, Last price  
71.40TWD
1D
1.28%
1Q
-29.60%
Jan 2017
-28.55%
IPO
-23.52%
Name

Formosa Laboratories Inc

Chart & Performance

D1W1MN
XTAI:4746 chart
P/E
68.01
P/S
1.97
EPS
1.05
Div Yield, %
1.40%
Shrs. gr., 5y
3.35%
Rev. gr., 5y
10.16%
Revenues
4.36b
+15.80%
02,505,914,0002,625,647,0002,524,282,0002,473,633,0002,496,224,0002,596,722,0003,189,380,0002,539,353,0002,687,731,0002,759,591,0003,075,457,0003,142,406,0003,765,504,0004,360,448,000
Net income
126m
-41.77%
0246,621,000231,067,0005,003,000-69,401,000262,495,000282,392,000483,441,000238,645,000176,821,000-41,062,000400,034,0001,249,096,000216,810,000126,243,000
CFO
827m
+28.54%
099,671,000-11,231,000171,135,00032,253,000280,408,000255,149,0001,110,075,000395,419,000-80,894,000289,924,000475,004,000311,157,000643,086,000826,600,000
Dividend
Aug 13, 20242 TWD/sh
Earnings
Jun 25, 2025

Profile

Formosa Laboratories, Inc. produces and sells active pharmaceutical ingredients (APIs) worldwide. The company offers APIs in the areas of anticancer, anti-inflammatory and analgesic agents, MRI enhancing agents, cholesterol and phosphate binders, CNS agents, immunomodulators, respiratory agents, steroids, vitamin D derivatives, and antibiotics. It also provides contract development and manufacturing services; solutions for manufacturing antibody-drug conjugates; and injectable manufacturing services. The company was founded in 1995 and is based in Taoyuan City, Taiwan.
URL
https://www.formosalab.com/
IPO date
Nov 27, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,360,448
15.80%
3,765,504
19.83%
3,142,406
2.18%
Cost of revenue
3,711,936
3,573,667
3,324,295
Unusual Expense (Income)
NOPBT
648,512
191,837
(181,889)
NOPBT Margin
14.87%
5.09%
Operating Taxes
194,650
116,371
44,008
Tax Rate
30.01%
60.66%
NOPAT
453,862
75,466
(225,897)
Net income
126,243
-41.77%
216,810
-82.64%
1,249,096
212.25%
Dividends
(120,256)
(240,512)
Dividend yield
0.98%
2.71%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
2,007,118
2,141,702
1,491,560
Long-term debt
2,100,037
1,702,721
1,981,734
Deferred revenue
18,227
16,989
Other long-term liabilities
84,781
111,976
74,572
Net debt
(353,176)
310,506
660,301
Cash flow
Cash from operating activities
826,600
643,086
311,157
CAPEX
(540,506)
(439,982)
(513,821)
Cash from investing activities
(1,257,426)
(540,721)
(589,491)
Cash from financing activities
117,457
447,945
439,020
FCF
227,742
168,769
(1,367,426)
Balance
Cash
2,510,488
1,630,531
1,093,481
Long term investments
1,949,843
1,903,386
1,719,512
Excess cash
4,242,309
3,345,642
2,655,873
Stockholders' equity
4,111,022
4,281,785
4,098,783
Invested Capital
8,266,593
8,239,116
8,420,028
ROIC
5.50%
0.91%
ROCE
5.23%
1.65%
EV
Common stock shares outstanding
120,491
120,884
121,497
Price
102.00
38.78%
73.50
21.49%
60.50
28.86%
Market cap
12,290,082
38.32%
8,884,974
20.87%
7,350,568
32.46%
EV
12,576,155
9,471,109
8,217,804
EBITDA
1,136,841
662,752
293,110
EV/EBITDA
11.06
14.29
28.04
Interest
34,735
19,319
28,051
Interest/NOPBT
5.36%
10.07%